Theriva Biologics, Inc.TOVXNYSE
Loading
Year-over-year research & development expense growth
| Period | Value |
|---|---|
| Q3 2025 | 30.62% |
| Q2 2025 | -34.20% |
| Q1 2025 | 2.84% |
| Q4 2024 | 5.56% |
| Q3 2024 | -7.42% |
| Q2 2024 | -14.63% |
| Q1 2024 | -17.56% |
| Q4 2023 | 4.74% |
| Q3 2023 | 27.86% |
| Q2 2023 | 5.24% |
| Q1 2023 | -3.06% |
| Q4 2022 | 19.49% |
| Q3 2022 | -26.26% |
| Q2 2022 | 34.19% |
| Q1 2022 | -6.55% |
| Q4 2021 | 40.92% |
| Q3 2021 | 2.07% |
| Q2 2021 | 72.81% |
| Q1 2021 | 14.20% |
| Q4 2020 | 7.11% |
| Q3 2020 | -42.98% |
| Q2 2020 | -1.96% |
| Q1 2020 | -15.15% |
| Q4 2019 | -53.50% |
| Q3 2019 | 59.75% |
| Q2 2019 | 7.28% |
| Q1 2019 | 17.61% |
| Q4 2018 | -27.76% |
| Q3 2018 | -20.32% |
| Q2 2018 | 5.99% |
| Q1 2018 | -10.28% |
| Q4 2017 | -9.21% |
| Q3 2017 | -14.37% |
| Q2 2017 | -20.27% |
| Q1 2017 | -9.96% |
| Q4 2016 | -4.70% |
| Q3 2016 | -1.44% |
| Q2 2016 | -12.15% |
| Q1 2016 | -7.94% |
| Q4 2015 | -11.83% |